PE20080116A1 - Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol - Google Patents

Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol

Info

Publication number
PE20080116A1
PE20080116A1 PE2007000231A PE2007000231A PE20080116A1 PE 20080116 A1 PE20080116 A1 PE 20080116A1 PE 2007000231 A PE2007000231 A PE 2007000231A PE 2007000231 A PE2007000231 A PE 2007000231A PE 20080116 A1 PE20080116 A1 PE 20080116A1
Authority
PE
Peru
Prior art keywords
formulation
weight
benzoxazole
fluor
hydroxyphenyl
Prior art date
Application number
PE2007000231A
Other languages
English (en)
Inventor
Mahesh K Krishnan
Mohamed Ghorab
Rolland W Carson
Shamin Hasan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20080116A1 publication Critical patent/PE20080116A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UN FORMULACION LIQUIDA O SEMISOLIDA QUE COMPRENDE: A) UN PORTADOR SELECCIONADO DE LAUROIL MACROGOL GLICERIDOS, ESTEAROIL MECROGOL GLICERIDOS, POLIETILENGLICOL, ENTRE OTROS QUE COMPRENDE DESDE 10% HASTA 99,99% EN PESO DE DICHA FORMULACION; B) UN SEGUNDO PORTADOR ADICIONAL SELECCIONADO DE CAPRILCAPROIL MACROGOLGLICERIDOS, LINOLEOIL MACROGOL GLICERIDOS, POLIALQUILEN GLICOL, POLIPROPILENGLICOL, ENTRE OTROS QUE COMPRENDE HASTA 70% EN PESO DE DICHA FORMULACION FARMACEUTICA; C) UN COMPONENTE EMULSIONANTE/SOLUBILIZANTE EN UNA CANTIDAD DE 0,01% HASTA 30% EN PESO DE DICHA FORMULACION FARMACEUTICA SELECCIONADO DE ALQUILO METALICO, COMPUESTOS DE AMONIO CUATERNARIO, SALES DE ACIDOS GRASOS, SULFOSUCCINATOS, ENTRE OTROS; D) UN COMPONENTE ANTICRISTALIZACION/SOLUBILIZACION EN UNA CANTIDAD DE 0,01% HASTA 30% SELECCIONADO DE POLIVINILPIRROLIDONA, CAPRILCAPROIL MACROGOLGLICERIDOS, ACEITE DE RICINO POLIETOXILADO, ENTRE OTROS; E) POR LO MENOS 90% EN PESO DE LA FORMA CRISTALINA DE MONOHIDRATO DE 2-(3-FLUOR-4-HIDROXIFENIL)-7-VINIL-1,3-BENZOXAZOL-5-OL. REFERIDA TAMBIEN A UN PROCESO DE PREPARACION. DICHA FORMULACION MINIMIZA LA CONVERSION POLIMORFICA SIENDO UTIL EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON LA MODULACION DEL RECEPTOR SELECTIVO ESTROGENICO ERBETHA
PE2007000231A 2006-03-06 2007-03-05 Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol PE20080116A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77989206P 2006-03-06 2006-03-06

Publications (1)

Publication Number Publication Date
PE20080116A1 true PE20080116A1 (es) 2008-02-25

Family

ID=38475772

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000231A PE20080116A1 (es) 2006-03-06 2007-03-05 Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol

Country Status (6)

Country Link
US (1) US20070207202A1 (es)
AR (1) AR059743A1 (es)
PA (1) PA8717801A1 (es)
PE (1) PE20080116A1 (es)
TW (1) TW200800178A (es)
WO (1) WO2007103877A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080176914A1 (en) * 2006-11-21 2008-07-24 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080146630A1 (en) * 2006-11-21 2008-06-19 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175900A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080132554A1 (en) * 2006-11-21 2008-06-05 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20090239920A1 (en) * 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080241234A1 (en) * 2006-11-21 2008-10-02 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080139633A1 (en) * 2006-11-21 2008-06-12 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3437599A1 (de) * 1984-10-13 1986-04-17 Dolorgiet GmbH & Co KG, 5205 St Augustin Ibuprofen enthaltende weichgelatinekapseln und verfahren zu ihrer herstellung
US5468502A (en) * 1994-12-20 1995-11-21 American Home Products Corporation Ibuprofen enhancing solvent system
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
JP2008521921A (ja) * 2004-12-02 2008-06-26 ワイス 置換ベンゾオキサゾールの製剤
US20060121110A1 (en) * 2004-12-02 2006-06-08 Wyeth Formulations of substituted benzoxazoles
WO2006060384A2 (en) * 2004-12-02 2006-06-08 Wyeth Formulations of substituted benzoxazoles
BRPI0608689A2 (pt) * 2005-03-08 2010-01-19 Wyeth Corp composto, composiÇço, processos para preparar monoidrato e a forma de cristal, e, uso de um monoidrato ou de uma forma de cristal
TW200800177A (en) * 2006-02-14 2008-01-01 Wyeth Corp Aqueous pharmaceutical formulations of ERβ selective ligands

Also Published As

Publication number Publication date
US20070207202A1 (en) 2007-09-06
TW200800178A (en) 2008-01-01
WO2007103877A2 (en) 2007-09-13
PA8717801A1 (es) 2009-04-23
AR059743A1 (es) 2008-04-23
WO2007103877A3 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
PE20080117A1 (es) Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
PE20080116A1 (es) Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
CL2012001841A1 (es) Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico.
ECSP056134A (es) Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA31766B1 (fr) Composés organiques
PE20090762A1 (es) Compuestos organicos
HK1113970A1 (en) Formulations for injection of catecholic butanes, including ndga compounds, into animals
UY30296A1 (es) Compuestos fenil amido heterociclicos condensados
GT200600400A (es) Formulaciones herbicidas liquidas de sulfonilurea
SV2010003717A (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos
GT200600346A (es) Nueva fórmula cristalina v de la agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen
AR069368A1 (es) Mezclas fungicidas
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
AR056746A1 (es) Mezclas insecticidas sinergicas para el tratamiento de las semillas
CL2008002241A1 (es) Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas.
GT200500358A (es) Compuestos organicos
AR059741A1 (es) Formulaciones farmaceuticas liquidas y semisolidas y procedimientos
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
MA32275B1 (fr) Preparations orales et injectables de composes de tetracycline
JP2010514733A5 (es)
TN2010000129A1 (fr) Nouvelles compositions a base de taxoides
AR025779A1 (es) Forma polimorfica cristalina de eletriptan, composicion farmaceutica que la contiene, uso de la forma y procedimiento de preparacion.
GT200800235A (es) Formulacion de medicamento liquida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal